Worth a repost20 Feb 2020 11:18
Traukamine potential for Faron.
"The maths is simple. Analysts say if a six-day course Tramaukine is be priced at say 4,500 euros, which is around 1,000 euros more than it costs for a one-day stay in an intensive care unit, then the market in Europe alone is worth 765million euros.
Add in the US – with potential sales of around 900millions euros a year – and suddenly you have drug with blockbuster potential (ie revenues of more than US$1billion, or 885million euros a year)"